CrossChx raises a $15 million Series C round from Khosla Ventures, Drive Capital and more

Next Story

Atom is the first of the new UK challenger banks out the gate — sort of

Healthcare identity startup CrossChx announced this morning that they raised a $15 million Series C financing round from Khosla Ventures, Drive Capital, Silicon Valley Bank, NCT Ventures and Moonshots Capital. This brings their total funding to $35 million since being founded in 2012.

The Columbus, OH startup’s primary product is a healthcare identity management system for patients called Queue. Queue and its accompanying tablet-based kiosk system allows patients to store their basic information like name, address, medical allergies, family history—all the things you have to re-enter every time you visit a new healthcare facility—into a portable, secure cloud profile.

This stored profile is then easily and securely transferable to the front desk of any healthcare provider that uses it and can speed up wait times for patients. Healthcare providers can also use Queue to manage patient arrivals internally. It’s a SaaS implementation and is already being used in 1,000 locations and is managing 50 million patient profiles.

QUEUE-6

I spoke with co-founder and CEO Sean Lane about Queue and inquired about whether patients will feel safe storing part of their healthcare profile in the cloud. The ex-airforce, ex-NSA software security expert assured me that the company goes above and beyond HIPAA requirements—”more than double the HIPAA security requirements” according to Lane.

He went on to explain that one of their main missions is to prevent duplicative patient profiles from existing in multiple systems or on paper in multiple healthcare offices like it does today. In his words, “offices access this info, only when they need it and are not burdened with storing this information themselves.” This system can also identify and prevent errors, as we’ve previously reported.

CrossChx plan to use the additional financing to increase their current staff of 120, extend their current tablet-based product distribution and also launch a new smartphone-based platform for patients.